[go: up one dir, main page]

CO6761387A2 - Compuesto de oxazol[5,4-b]piridin 5-ilo - Google Patents

Compuesto de oxazol[5,4-b]piridin 5-ilo

Info

Publication number
CO6761387A2
CO6761387A2 CO13139854A CO13139854A CO6761387A2 CO 6761387 A2 CO6761387 A2 CO 6761387A2 CO 13139854 A CO13139854 A CO 13139854A CO 13139854 A CO13139854 A CO 13139854A CO 6761387 A2 CO6761387 A2 CO 6761387A2
Authority
CO
Colombia
Prior art keywords
pyridin
oxazol
compound
oxazolo
cancer
Prior art date
Application number
CO13139854A
Other languages
English (en)
Inventor
David Andrew Coates
Raymond Gilmour
Jose Alfredo Martin
De La Nava Eva Maria Martin
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46162794&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6761387(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO6761387A2 publication Critical patent/CO6761387A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invención se refiere a compuestos de oxazolo[5,4-b]piridin-5-ilo útiles en el tratamiento de cáncer.
CO13139854A 2010-12-03 2013-06-11 Compuesto de oxazol[5,4-b]piridin 5-ilo CO6761387A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10382329 2010-12-03
US201161439151P 2011-02-03 2011-02-03

Publications (1)

Publication Number Publication Date
CO6761387A2 true CO6761387A2 (es) 2013-09-30

Family

ID=46162794

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13139854A CO6761387A2 (es) 2010-12-03 2013-06-11 Compuesto de oxazol[5,4-b]piridin 5-ilo

Country Status (27)

Country Link
US (1) US8288548B2 (es)
EP (1) EP2646445B1 (es)
JP (1) JP5726321B2 (es)
KR (1) KR101514162B1 (es)
CN (1) CN103221415B (es)
AR (1) AR083868A1 (es)
AU (1) AU2011337033A1 (es)
BR (1) BR112013013282A2 (es)
CA (1) CA2819822C (es)
CL (1) CL2013001518A1 (es)
CO (1) CO6761387A2 (es)
CR (1) CR20130182A (es)
DO (1) DOP2013000116A (es)
EA (1) EA021241B1 (es)
EC (1) ECSP13012653A (es)
ES (1) ES2567271T3 (es)
GT (1) GT201300139A (es)
IL (1) IL226054A0 (es)
MX (1) MX2013006184A (es)
NZ (1) NZ610289A (es)
PE (1) PE20140008A1 (es)
PH (1) PH12013501115A1 (es)
SG (1) SG190680A1 (es)
TW (1) TWI410425B (es)
UA (1) UA109677C2 (es)
WO (1) WO2012074761A1 (es)
ZA (1) ZA201303580B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102279347B1 (ko) 2016-12-15 2021-07-21 한국생명공학연구원 피리딘계 화합물을 유효성분으로 함유하는 dyrk 관련 질환의 예방 또는 치료용 약학적 조성물
CA3078232A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. Use of p38 inhibitors to reduce expression of dux4
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20011083A1 (es) 2000-02-15 2001-10-26 Sugen Inc 2-indolinas sustituidas con pirroles inhibidoras de proteinquinasas
CO5271680A1 (es) * 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
ATE309997T1 (de) * 2001-03-09 2005-12-15 Pfizer Prod Inc Entzündungshemmende benzimidazolverbindungen
US7320995B2 (en) * 2002-08-09 2008-01-22 Eli Lilly And Company Benzimidazoles and benzothiazoles as inhibitors of map kinase
TWI332003B (en) * 2004-01-30 2010-10-21 Lilly Co Eli Kinase inhibitors
AU2005251735A1 (en) 2004-06-04 2005-12-22 Amphora Discovery Corporation Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
US7723340B2 (en) 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7473784B2 (en) * 2005-08-01 2009-01-06 Bristol-Myers Squibb Company Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
AU2008282728B2 (en) * 2007-08-02 2012-04-19 Amgen Inc. Pl3 kinase modulators and methods of use

Also Published As

Publication number Publication date
EA201390620A1 (ru) 2013-10-30
PH12013501115A1 (en) 2013-07-22
DOP2013000116A (es) 2014-10-31
GT201300139A (es) 2014-04-08
EP2646445A1 (en) 2013-10-09
MX2013006184A (es) 2013-07-15
NZ610289A (en) 2015-07-31
IL226054A0 (en) 2013-06-27
PE20140008A1 (es) 2014-01-31
SG190680A1 (en) 2013-07-31
UA109677C2 (ru) 2015-09-25
CA2819822A1 (en) 2012-06-07
EP2646445B1 (en) 2016-03-16
US8288548B2 (en) 2012-10-16
TW201300397A (zh) 2013-01-01
CL2013001518A1 (es) 2013-11-04
ZA201303580B (en) 2014-12-23
AR083868A1 (es) 2013-03-27
JP2013544835A (ja) 2013-12-19
EA021241B1 (ru) 2015-05-29
CR20130182A (es) 2013-07-09
US20120142724A1 (en) 2012-06-07
ES2567271T3 (es) 2016-04-21
CN103221415B (zh) 2015-06-17
CN103221415A (zh) 2013-07-24
ECSP13012653A (es) 2013-08-30
TWI410425B (zh) 2013-10-01
BR112013013282A2 (pt) 2016-09-06
KR101514162B1 (ko) 2015-04-21
KR20130093140A (ko) 2013-08-21
JP5726321B2 (ja) 2015-05-27
CA2819822C (en) 2015-07-21
WO2012074761A1 (en) 2012-06-07
AU2011337033A1 (en) 2013-07-18

Similar Documents

Publication Publication Date Title
CL2016001733A1 (es) Compuestos intermediarios para la preparación de compuestos derivados de piperidinona como inhibidores mdm2 para el tratamiento de cáncer div. sol. 3415-12.
CR20110046A (es) Amidofenoxiindazoles utiles como inhibidores de c-met
PE20140864A1 (es) COMPUESTO DE IMIDAZO[4,5-C]QUINOLIN-2-ONA COMO INHIBIDOR DE PI3K/mTOR
MX340490B (es) Derivados de pirazolo [1, 5a] pirimidina y de tieno [3, 2b] pirimidina como moduladores de la cinasa asociada al receptor de la interleucina 4 (irak4).
CR20130539A (es) Triazolopiridinas
AU2014270524A8 (en) 2-phenylimidazo [1,2-a]pyrimidines as imaging agents
CR20130349A (es) COMPUESTOS SUSTITUIDOS DE N-(1H- INDAZOL-4-IL) IMIDAZO [1,2-a] PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE LA TIROSINA QUINASA RECEPTORA DE TIPO III
AU2012213775A8 (en) 7-azaindole derivatives
ZA201307783B (en) Tri-and tetracylic pyrazolo[3,4-b]pyridine compounds as antineoplastic agent
CR20120295A (es) Triazolopiridinas
TN2012000401A1 (en) Heterocyclic compound
CR20110427A (es) Derivados de triazolo [4,3-b] piridazina y sus usos para el cáncer de próstata
CR20120637A (es) Triazolopiridinas sustituidas
EA201290744A1 (ru) Имидазо[1,2-b][1,2,4]триазины в качестве c-met ингибиторов
AU2011325479A8 (en) 7-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyrazine derivatives
CR20150245A (es) Proceso novedoso para la elaboración de compuestos para uso en el tratamiento de cáncer
HUE042978T2 (hu) Antibakteriális ciklopenta[c]pirrol-szubsztituált 3,4-dihidro-1H-[1,8]naftiridon-származékok
CR20130041A (es) ISOXAZOLO[5,4-b]PIRIDINAS HERBICIDAS
AU2012342891A8 (en) 3-Cyanoaryl-1H-pyrrolo[2.3-b]pyridine derivatives
CO6541577A2 (es) Nuevas formas polimorfas de {4.6- diamino -2-[1-(2-fluorobencil)-1h- pirazolo[3.4-b]piridin-3il] pirimidin -5il} carbamato de metilo
CO6761387A2 (es) Compuesto de oxazol[5,4-b]piridin 5-ilo
EA201490092A1 (ru) Кристаллы конденсированного гетероциклического соединения
MY164138A (en) Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring
CR20130005A (es) Agentes terapéuticos 976
MY164133A (en) Carboxylic acid derivatives having an oxazolo[5,4-b]pyridine ring

Legal Events

Date Code Title Description
FG Application granted